Novo Nordisk released full results from a late-stage trial showing its Wegovy injection helped children ages 6 to under 12 with obesity lose weight. The company said the drug significantly lowered body mass index (BMI).
Across the 68-week trial, Wegovy reduced BMI by an estimated 19.7 percentage points on average compared with a placebo, assuming patients stayed on treatment. BMI fell 17.4% among children receiving the drug and rose 2.2% among those receiving a placebo. Including children who stopped treatment, the estimated reduction was 16.2 percentage points more than placebo. All 167 children received lifestyle changes, including a reduced-calorie diet and more physical activity.
Dr. Andrea Traina, Novo's medical director lead of obesity, said the disease imposes "a very significant disease burden in this very young patient population." Novo said the drug's safety and tolerability in children were consistent with trials in adults, and it observed no safety concerns related to growth or pubertal development.
Wegovy is already approved for obesity in children 12 and older. The report says no approved medications currently exist for children under 12.
Traina said the two-year study does not show whether earlier treatment changes the long-term course of obesity, or what treatment and maintenance might look like as children become adults. She called that "an evidence gap."